Biotest AG BIO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- €41.80
- Day Range
- €41.60–41.60
- 52-Week Range
- €39.60–44.00
- Bid/Ask
- €0.00 / €0.00
- Market Cap
- €1.65 Bil
- Volume/Avg
- 0 / 199
Key Statistics
- Price/Earnings (Normalized)
- 11.45
- Price/Sales
- 2.42
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Biotest AG is a supplier of biological medicines. The company produces its products from human blood plasma or manufactured by using biotechnology methods. It is engaged in the area of hematology, clinical immunology, and intensive care medicine. The operating business segments are Therapy, Plasma and Services, and Other segments. It generates maximum revenue from the Therapy segment. Geographically, it derives a majority of revenue from Central Europe and also has a presence in other countries.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 2,426
- Website
- https://www.biotest.com
Comparables
Valuation
|
Metric
|
BIO
|
NYKD
|
ATAI
|
|---|---|---|---|
Price/Earnings (Normalized) | 11.45 | — | — |
Price/Book Value | 3.32 | 2.54 | 1.31 |
Price/Sales | 2.42 | 27.03 | 966.11 |
Price/Cash Flow | 14.01 | — | — |
Price/Earnings
BIO
NYKD
ATAI
Financial Strength
|
Metric
|
BIO
|
NYKD
|
ATAI
|
|---|---|---|---|
Quick Ratio | 0.84 | 6.95 | 9.02 |
Current Ratio | 1.96 | 6.95 | 9.22 |
Interest Coverage | 3.61 | — | −14.49 |
Quick Ratio
BIO
NYKD
ATAI
Profitability
|
Metric
|
BIO
|
NYKD
|
ATAI
|
|---|---|---|---|
Return on Assets (Normalized) | 8.47% | −19.18% | −28.57% |
Return on Equity (Normalized) | 26.25% | −26.31% | −33.78% |
Return on Invested Capital (Normalized) | 13.35% | −30.96% | −30.99% |
Return on Assets
BIO
NYKD
ATAI
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Fbrchpqpxk | Vtjk | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Czbxwxwl | Dmntpbz | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Tldjqfys | Vmbmpm | $98.1 Bil | |
MRNA
| Moderna Inc | Kzjlbrdx | Lwnz | $39.1 Bil | |
ARGX
| argenx SE ADR | Tppjchk | Bbmj | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Lnkgblc | Chvn | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Slnscngc | Pyzxz | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xvstjfxp | Kxpcpmt | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Pnmkdhgxjh | Pwqkjk | $12.5 Bil | |
INCY
| Incyte Corp | Sdxtpnxx | Vrbpsl | $11.9 Bil |